Extendicare Inc. (EXE:CN) (OTC: EXETF), currently trading at $7.43, received a new Buy rating from Canaccord Genuity analysts, accompanied by a price target of C$13.00. The stock has shown remarkable ...

PDI locks in more than $69m from two strategic investors, heightening potential M&A activity of the Bankan gold project.

Power Metals (TSX-V PWM) has retained Canaccord Genuity as financial advisor due to a high-level of interest in its Case Lake ...

Canaccord Genuity has initiated coverage on Opthea (ASX:OPT), and is giving the stock a BUY rating and a target price of ...

Canaccord Genuity adjusted its price target for Lavoro stock (NASDAQ:LVRO), lowering it to $5.50 from the previous $6.25. Despite the reduction, the firm continues to recommend a Buy rating for the ...

Canaccord raised the firm’s price target on AxoGen (AXGN) to $22 from $18 and keeps a Buy rating on the shares. The firm updated its model ...

In a report released today, Aravinda Galappatthige from Canaccord Genuity maintained a Hold rating on BCE (BCE – Research Report), with a price ...

VANCOUVER, BC, Jan. 30, 2025 /CNW/ - Power Metals Corp ("Power Metals" or the "Company") (TSXV: PWM) (FRANKFURT: OAA1) (OTCQB: PWRMF) is pleased to announce the appointment of Canaccord Genuity ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial succeeds. But the broker said that with a successful Phase III trial ...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...